翰宇药业与Dr. Reddy’s签署多肽原料药战略合作非约束性条款清单，推进全球...

Hybio Pharmaceutical and Dr. Reddy’s Sign non-binding strategic cooperation term sheet on Peptide APIs to Advance Global Peptide Collaboration

12月25日，翰宇药业与全球知名制药企业Dr.Reddy’s（瑞迪博士实验室）在北京举行签约仪式，双方正式签署多肽原料药及相关制剂领域的战略合作非约束性条款清单，标志着双方战略合作的良好开端。

December 25 — Hybio Pharmaceutical and Dr. Reddy’s, a global pharmaceutical company, held a signing ceremony in Beijing, where the two parties formally executed a non-binding strategic cooperation term-sheet covering peptide active pharmaceutical ingredients (APIs) and related formulations, marking a positive commencement of exploration of their strategic collaboration.

翰宇药业创始人、董事长兼总裁曾少贵先生与Dr.Reddy’s 首席执行官 Erez Israeli 先生代表双方签署该条款清单。翰宇药业董事兼执行总裁唐洋明先生、沈亚平先生，Dr.Reddy’s品牌市场（印度及新兴市场首席执行官 M.V. Ramana 先生、中国及大中华区集群负责人 Satheeshkumar Sriharan 先生等领导共同出席并见证签约仪式。

The term-sheet was signed by Mr. Zeng Shaogui, Founder, Chairman and President of Hybio Pharmaceutical, and Mr. Erez Israeli, Chief Executive Officer of Dr. Reddy’s, on behalf of the respective parties. The ceremony was attended and witnessed by senior executives from both sides, including Mr. Tang Yangming and Mr. Shen Yaping, Directors and Executive Vice Presidents of Hybio Pharmaceutical, as well as Mr. M.V. Ramana , Chief Executive Officer – Branded Markets (India and Emerging Markets) of Dr. Reddy’s, and Mr. Satheeshkumar Sriharan, Head of China and Greater China Cluster at Dr. Reddy’s.

此次合作的达成源于双方前期的深度磋商与战略契合。2025年9月，Dr.Reddy’s全球CEO率队到访翰宇总部及生产基地，双方就多肽药物研发创新、全球商业化策略及潜在战略合作方向等关键议题展开深度讨论，并在CPHI等国际会议期间进行了多轮面对面交流。

The collaboration is the result of extensive preliminary discussions and strong strategic alignment between the two companies. In September 2025, a delegation led by Dr. Reddy’s Global CEO visited Hybio Pharmaceutical’s headquarters and manufacturing facilities. During the visit, the parties conducted in-depth discussions on peptide drug R&D innovation, global commercialization strategies, and potential strategic cooperation directions, followed by multiple rounds of face-to-face exchanges at international industry events, including CPHI.

根据合作框架，双方已就多个多肽原料药品种的合作范围及整体战略达成初步共识。翰宇药业将作为Dr.Reddy’s 多肽制剂业务的优先原料药开发与供应合作伙伴；在部分产品上，双方将采用优先或半独家合作安排，并在满足最低采购量承诺的前提下，推动长期稳定的全球合作。双方还将围绕仿制药、寡核苷酸等方向展开探索性讨论，布局更广泛的治疗领域。

Pursuant to the cooperation framework, the parties have reached preliminary consensus on the scope of cooperation and overall strategy for multiple peptide API products. Hybio Pharmaceutical will act as a preferred partner for the development and supply of peptide APIs for Dr. Reddy’s peptide formulation business. For certain products, the collaboration may adopt priority or semi-exclusive arrangements, subject to minimum purchase commitments, with a view to establishing a long-term and stable global partnership. In addition, the parties will conduct exploratory discussions regarding potential cooperation in generic drugs, oligonucleotides, and other areas, with the aim of expanding into a broader range of therapeutic fields.

Dr.Reddy’s在全球80多个市场拥有成熟的法规注册、制剂开发及商业化网络，并将多肽业务视为战略性增长方向。翰宇药业则在多肽原料药领域拥有先进的研发平台、规模化制造能力及持续扩展的产品管线。双方优势互补，通过早期研发协同，有望实现开发效率提升，更快地将高质量多肽产品推向全球市场。

Dr. Reddy’s operates in more than 80 markets worldwide, with established capabilities in regulatory registration, formulation development, and commercialization, and regards peptides as a strategic growth area. Hybio Pharmaceutical, meanwhile, possesses advanced R&D platforms, scalable manufacturing capabilities, and a continuously expanding product pipeline in the peptide API field. By leveraging their complementary strengths and engaging in early-stage R&D collaboration, the parties expect to enhance development efficiency and accelerate the global delivery of high-quality peptide products.

翰宇药业董事长兼总裁曾少贵表示：“此次与Dr.Reddy’s的战略合作，是公司多肽国际化战略布局中的重要里程碑。未来，双方将以多肽原料药合作为起点，持续深化在多肽制剂开发及寡核苷酸等领域的合作探索，充分发挥各自在技术、产能、市场等方面的优势，推动多肽药物领域的创新发展。”

Mr. Zeng Shaogui, Chairman and President of Hybio Pharmaceutical, commented: “This strategic cooperation with Dr. Reddy’s represents an important milestone in Hybio Pharmaceutical’s global peptide strategy. Starting with peptide APIs, the two parties will continue to deepen collaboration in peptide formulation development and explore opportunities in oligonucleotides and other areas, fully leveraging our respective strengths in technology, manufacturing capacity, and market access to promote innovation in the peptide therapeutics field.”

Dr. Reddy’s首席执行官 Erez Israeli表示：“翰宇药业在多肽原料药领域积淀的深厚技术实力与成熟产业化能力，与我们的全球制剂研发、注册申报及市场网络优势形成高度互补。我们坚信，双方的深度合作不仅能实现商业价值的共赢，更有望在未来形成具备全球示范意义的多肽产业合作模式，为全球多肽产业的高质量发展贡献力量。”

Mr. Erez Israeli, Chief Executive Officer of Dr. Reddy’s, stated:“Hybio Pharmaceutical’s technical expertise and well-established industrialization capabilities in peptide APIs are highly complementary to our global strengths in formulation R&D, regulatory submissions, and market networks. We firmly believe that this collaboration will not only generate mutual commercial value, but also has the potential to establish a globally representative model for peptide industry cooperation and contribute to the high-quality development of the global peptide sector.”

关于翰宇药业

关于翰宇药业

一家专注于创新药物研发、生产与销售的A股上市的国家级高新技术企业，深耕多肽药物20余年，拥有覆盖全球主流多肽靶点的完整制剂管线，包括但不限于GLP-1R/GIPR/GCGR三重受体激动剂原创新药、瑞他鲁肽、替尔泊肽、司美格鲁肽、利拉鲁肽等全球重磅多肽ANDA制剂，累计授权国内外专利近500余项，为GLP-1日制剂利拉鲁肽ANDA全球首家在美国FDA获批上市企业，产品已进入欧美规范市场。

About Hybio Pharma

An A-share listed, state-level high-tech enterprise dedicated to the R&D, manufacturing, and marketing of innovative medicines. With over 20 years of focus on peptide therapeutics, Hybio Pharma has built a comprehensive formulation pipeline covering the world’s major peptide targets. Its portfolio includes first-in-class triple agonists for GLP-1R/GIPR/GCGR, as well as global blockbuster peptide ANDA products such as retatrutide, tirzepatide, semaglutide, and liraglutide. Hybio Pharma owns nearly 500 granted patents at home and abroad and was the first company worldwide to receive U.S. FDA approval for a generic daily GLP-1 liraglutide injection. Its products are already marketed in the regulated markets of Europe and the United States.

关于Dr. Reddy's

印度大型制药公司Dr.Reddy’s（瑞迪博士实验室）总部设在印度海德拉巴，成立于1984年，是一家原料制剂一体化的跨国制药公司，致力于为人类健康事业提供买得起的、创新的药品。通过自身完整的药品价值链，该公司提供包括原料药、仿制药、生物仿制药、差异化制剂、新化学实体等一系列产品组合和多种医药定制服务。

About Dr. Reddy’s

A major Indian pharmaceutical company headquartered in Hyderabad, founded in 1984, Dr. Reddy’s Laboratories is a vertically integrated multinational dedicated to providing affordable, innovative medicines that improve human health. Through its end-to-end value chain, Dr. Reddy’s supplies active pharmaceutical ingredients (APIs), generic drugs, biosimilars, differentiated formulations, and new chemical entities (NCEs), together with a broad range of custom pharmaceutical services.

(翰宇药业)